Table 2.
IL-6 challenge does not induce pathology in SOCS3−/Δvav mice
| SOCS3+/fl | SOCS3−/Δ vav | |||
|---|---|---|---|---|
| Peripheral Blood (×106/mL) | Platelets | Saline | 1272±399 | 1313±177 |
| IL-6 | 1863±289 | 1564±428 | ||
|
| ||||
| Leukocytes | Saline | 3±2 | 6±5 | |
| IL-6 | 5±2 | 5±1 | ||
|
| ||||
| Granulocytes | Saline | 0.3±0.1 | 0.4±0.5 | |
| IL-6 | 0.4±0.2 | 0.4±0.2 | ||
|
| ||||
| B cells | Saline | 2±2 | 4±3 | |
| IL-6 | 3±1 | 3±1 | ||
|
| ||||
| T cells | Saline | 0.7±0.3 | 2±1 | |
| IL-6 | 2±0.4 | 1±1 | ||
|
| ||||
| Spleen (×106 cells) | Weight (mg) | Saline | 73±6.4 | 133±77 |
| IL-6 | 121±18* | 169±26 | ||
|
| ||||
| Leukocytes | Saline | 75±3 | 142±94 | |
| IL-6 | 150±28 | 164±18 | ||
|
| ||||
| Granulocytes | Saline | 0.7±0.3 | 6±7 | |
| IL-6 | 0.8±0.2 | 4.3±0.9 | ||
|
| ||||
| Erythroid cells | Saline | 0.4±0.1 | 4.1±4.2 | |
| IL-6 | 14±4 | 16±6 | ||
|
| ||||
| B cells | Saline | 46±5 | 88±61 | |
| IL-6 | 87±18 | 87±10 | ||
|
| ||||
| T cells | Saline | 23±2 | 34±15 | |
| IL-6 | 33±5 | 38±4 | ||
|
| ||||
| BM (×106 cells) | Total cells | Saline | 19±0.1 | 14±6 |
| IL-6 | 22±3 | 16±3 | ||
|
| ||||
| Granulocytes | Saline | 6±0.7 | 7±2 | |
| IL-6 | 9±1 | 11±2 | ||
|
| ||||
| Erythroid cells | Saline | 6±1 | 3±2 | |
| IL-6 | 6±1 | 2±1 | ||
|
| ||||
| B cells | Saline | 4±0.3 | 2±1 | |
| IL-6 | 5±2 | 1±0.3 | ||
Mice were injected with 1 μg IL-6 twice daily for 7 days and analysed day 8. Gr1, Ter119, B220 and Thy1 were used as markers for granulocytes, erythroid cells, B cells and T cells, respectively. Leukocyte number from bone marrow is from 2 femurs. Figures represent mean and standard deviation from 2 (saline-treated) or 4 (IL-6-treated) mice per group.
*
p<0.05, saline-treated versus IL-6-treated.